Acute bronchitis is a common lower respiratory tract infection that, for about 90% of cases, is thought to have viral origins[76][77] and is characterized by excessive coughing and sputum in the lungs which causes a coarse snoring-like sound (sometimes called rales or rhonchi).[78] It is one of the top ten reasons patients seek medication from a doctor[76][79] and despite being thought to usually not be bacterial in nature, it is usually treated with antibiotics (65-80% of cases[76][80]); pelargonium sidoides is thought to be beneficial due to it traditionally being used for this condition, and having both potent anti-viral properties against most lung viral infections ex vivo[70] and antibacterial properties that reduce adhesion[62][63] and are thought to be less likely to cause bacterial resistance problems since they are not necessarily cytotoxic to the bacteria.
Diagnosis of acute bronchitis tends to focus around hoarse coughing (85% of patients reporting a cough within two days, and mostly gone by two weeks but has been noted to persist for 8 weeks in a few patients); usually alongside the cough there exists hoarseness, rhonchi (a hoarse snore-like sound from the lungs caused by sputum buildup), and vitality symptoms like fatigue, fever, and general malaise.[76]
Acute bronchitis is a conditions characterized by hoarse coughing, wheezing, and sputum buildup in the lungs that can cause something like a snoring sound in the lower lungs (rhonchi) that usually lasts just over two weeks but may persist for a month of longer in a select few patients
In adults with acute bronchitis given supplemental pelargonium sidoides (EPs7630) at thirty drops thrice daily for one week and assessed by the Bronchitis Severity Score (BSS) (validated subjective measure for acute bronchitis[81]) noted that the improvement in symptoms over one week seen with the supplement (8.4 on the rating scale to 2.5 on average; 70% reduction) exceeded that of placebo (8 down to 4.8; 40% reduction) with improved symptoms occurring at the first followup of 3-5 days.[29] EPs7630 was also more effective at lowering the rating below 3 (64.4% of EPs7630 and 37.9% of placebo) and in inducing a 7 point reduction on the scale (43.3% of EPs7630 and 23.0% of placebo), and in 77.1% of treatment group rhonchi (coarse rattling in airways from secretion) was abolished alongside cough (83.7% of treatment) and fever (96.9%).[29] Elsewhere, adults with acute bronchitis given a similar protocol (4.5mL thrice daily for a week and assessed by the BSS in a double blind manner) replicated such a reduction in overall symptoms of bronchitis and improved self-reported quality of life relative to placebo.[45]
Once study that encompasses both adults (30 drops thrice daily) and children (20 drops thrice daily if between 6-12yrs, 10 drops thrice daily for those under six) over two weeks was able to significantly reduce overall scores on the BSS in all age groups, with a 86% reduction in the entire sample with a similar magnitude in children (86%) and those under three years of age (77%).[44] In both adults and children, this study also confirmed large reductions in the comorbidities of acute bronchitis including reductions in fever (94.6%), chest pain when coughing (94.1%) and the cough itself (59.7%), fatigue (80.2%), rhonchi (93.1%) and sputum (80.7%), headache (90.7%), and shortness of breath (93.2%) after two weeks.[44] Efficacy in children of all age groups (0-18) is similar to the efficacy seen in adults.
When looking the course of treatment, it appears that benefits may come within two[46] or three[29] days of supplementation but are greater at day seven (relative to day three)[29] and are greater after two weeks relative to one;[44] this suggests time-dependent benefits up until two weeks where symptoms are mostly abolished. Dosage wise, in adults given supplements of either 10mg thrice daily, 20mg thrice daily, or 30mg thrice daily it seems that while 20-30mg thrice daily (60-90mg each day) is slightly better than 10mg that there is no difference between the two higher doses and that all are better than placebo.[31] When comparing the efficacy of EPs7630 against other conventional therapies, a meta-analysis[82] (referencing a one study behind a language barrier) found that 30 drops of EPs7630 thrice daily is nonsignificantly better than 200mg of N-acetylcysteine twice daily in children for treating symptoms of acute bronchitis after seven days (although symptoms were cleared up faster with EPs7630).
In both children and adults specifically with acute bronchitis, supplementation of the standardized extract of pelargnoium sidoides appears to be highly effective in reducing respiratory side-effects
One study has been conducted in bronchitis in general (acute bronchitis, but also persons with chronic bronchitis experiencing an acute increase in symptoms) with the standard 30 drop thrice daily dosing schedule of EPs7630 noted whole-group improvement; while there wasn't a large sample of persons with acute bronchitis given supplementation (n=19) there did not appear to be any difference in the benefits achieved.[46]
Appears to also be beneficial for those with chronic bronchitis experiencing a short term increase in symptoms, but the body of evidence is less robust for this specifically
In adults with chronic obstructive pulmonary disease (COPD; characterized by limited airflow associated with inflammation[83]) given 30 drops of EPs7630 daily over the course of 24 weeks noted that there was a significantly reduced need for antibiotic treatment (73.3% in placebo and 37.8% in EPs7630) and improved breathing as assessed by the SGRQ (St. George's Respiratory Questionnaire[84]) and the reduced exacerbations of symptoms.[30]
There appears to be benefit to adults with COPD (impairment of lung function not associated with viral infections, but with inflammation) by reducing the need for subsequent antibiotic treatment and reduced exacerbations of symptoms